Collaborative Training Partnerships

Oxford Biomedica is delighted to be leading a Biotechnology and Biological Sciences Research Council (BBSRC) funded Collaborative Training Partnership (CTP) doctoral training programme called Advanced Bioscience of Viral Products (ABViP), together with our academic partners at the University of Oxford (UOXF) and University College London (UCL).  

ABViP is a comprehensive, multidisciplinary training programme designed and led by industry. It aims to deliver the next generation of bioscience leaders who will advance research on the underpinning bioscience of viral products for future gene therapies and vaccines. The ABViP CTP will train a cohort of 24 students (18 x CTP-funded, 6 x partner-funded) over a three-year period of student intake to address the acute viral vector skills shortage.

Partners will bring complementary expertise in Lentiviral and Adeno-Associated viral vector bioprocessing, novel analytics and data science methodologies and viral vaccine design, development, and characterisation. The academic partners also bring extensive experience of leading high-quality, internationally leading doctoral training programmes including UCL’s BBSRC London Interdisciplinary Doctoral Programme DTP (LIDo) and EPSRC CDT in Bioprocess Engineering Leadership and UOXF’s BBSRC Interdisciplinary Bioscience DTP, MRC Interdisciplinary Medical Research DTP, and IBM/EPSRC Computational Discovery programme.

Submitting Project Proposals

Interested principal investigators (academic supervisors) already working or experienced in a relevant field, and currently holding a position at either the UOXF or UCL, are encouraged to submit project proposals for review and consideration for funding by the ABViP Management Board. Please refer to the section headed “Proposed research themes for the ABViP CTP include” below for an overview of potential research themes to be considered in any submission.

The application form for potential supervisors can be found below (closing date for applications 12:00 on 6th December 2021). The ABViP Management Board will review applications in relation to the fit with the overarching aims of ABViP and its relevance to associated research themes. A total of eight projects will receive funding for doctoral training (PhD, DPhil) students starting in the September/October 2022 intake.

> Click here to download all assets <

Potential CTP Student Applicants

At Oxford Biomedica we recognise the importance of investing in early talent, and we are passionate about developing the scientific leaders of the future within cell and gene therapy and viral products, especially as the industry is booming.

However, we understand the challenges for those who are thinking about their next steps including, the barriers PhD/DPhil study can bring, whether it be financial or career starting opportunities, which contribute to a skills gap within this sector.

Therefore, we are launching the CTP in ABViP programme, which is a comprehensive, multidisciplinary training programme supported and fully funded by the BBSRC, OXB, UOXF and UCL. This will help us to diversify our ways of thinking, and close the industry skill gap, so we can continue innovating and delivering lifesaving gene therapies to patients.

The aim of the CTP is to attract the very best people to help build a pool of the scientific leaders of the future for such an important aspect of medicines development. Students trained through the ABViP CTP will gain a holistic insight into the research and development activities required to develop the medicines of the future, with the ability to see the world of medicines development through both an academic and industrial lens.

We are kicking off this programme with our first cohort (due to start September/October 2022), with eight PhD studentship projects that will support cell and gene therapy excellence.

Notable Dates

Applications & Projects Open: December

Application Deadlines: January

Final interviews and appointments: mid-February

Start Date: September/October 2022